Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy
Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy
复制标题
DOI：
10.1111/j.1365-2354.2006.00718.x
复制
发表时间：
2007-05-01
影响因子：
2.1
通讯作者：
Chroni, E.
中科院分区：
文献类型：
--
作者：
Argyriou, A. A.;Polychronopoulos, P.;Chroni, E.
目前的前瞻性研究旨在追踪顺铂加紫杉醇（DDP+P）诱导的神经病变的发生率和严重程度，并确定其临床和电生理模式。此外，它试图描述其演变通过化疗期间周围神经病变（PN）的过程以及停药后3个月。13名成人患者参加了这项研究，他们计划接受6个疗程的累积DDP+P-based方案治疗非髓系恶性肿瘤。这些患者在基线、化疗期间和停药后3个月进行临床和电生理监测。通过改良的PN评分来总结PN的严重程度。13例患者中有9例（69.2%）出现PN的证据。表现出一定程度PN的患者的平均PN评分为17.3 +/- 6.1（范围9-28）。所有关于运动传导速度（MCV）变量的纵向比较均未达到显著性。相比之下，基线和每次后续研究的平均变化的比较显示，所有检查的感觉动作电位都显着下降。停止化疗3个月后的随访评估显示，DDP+ p诱导的神经病变持续存在并随时间进展。我们的研究结果表明，大多数接受全剂量DDP+ p为基础的方案治疗的患者会出现轻度至中度的轴突性PN，主要是感觉性PN，并在化疗停止后持续数月。
The current prospective study sought to trace the incidence and severity of cisplatin plus paclitaxel (DDP+P)-induced neuropathy and to determine its clinical and electrophysiological pattern. Furthermore, it was attempted to describe its evolution by following up the course of peripheral neuropathy (PN) during chemotherapy as well as 3 months after its discontinuation. Thirteen adult patients scheduled to be treated with six courses of cumulative DDP+P-based regimens for a non-myeloid malignancy participated in this study. These patients were clinically and electrophysiologically monitored at baseline, during chemotherapy and 3 months after its discontinuation. The severity of PN was summarized by means of a modified PN score. Evidence of PN was disclosed in nine of the 13 patients (69.2%). The mean PN score for patients that manifested some grade of PN was 17.3 +/- 6.1 (range 9-28). All longitudinal comparisons concerning the motor conduction velocities (MCV) variables failed to reach significance. By contrast, comparisons of the mean changes at baseline and each of the follow-up studies revealed a significant decrease in all sensory action potentials examined. The follow-up evaluation performed 3 months after the discontinuation of chemotherapy showed that the DDP+P-induced neuropathy persists and progresses over time. Our results indicate that the majority of patients treated with a DDP+P-based regimen at full dose intensities would manifest an axonal, predominately sensory PN, of mild to moderate severity, which would persist for several months after the discontinuation of chemotherapy.